Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
about
Same Data; Different InterpretationsDose-dense paclitaxel plus carboplatin as neoadjuvant chemotherapy for advanced ovarian, fallopian tube, or primary peritoneal carcinomas.Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.MicroRNA-135a-3p as a promising biomarker and nucleic acid therapeutic agent for ovarian cancer.Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer.Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.Prognostic and clinicopathological significance of Cacna2d1 expression in epithelial ovarian cancers: a retrospective studyFifth annual workshop of cytoreductive surgery for advanced ovarian cancer and peritoneal surface malignancies.Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis.Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.Chemotherapeutic dosing implicated by pharmacodynamic modeling of in vitro cytotoxic data: a case study of paclitaxel.ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance).An update on current and emerging therapies for epithelial ovarian cancer: Focus on poly(adenosine diphosphate-ribose) polymerase inhibition and antiangiogenesis.An Open-Label, Randomized, Parallel, Phase II Trial to Evaluate the Efficacy and Safety of a Cremophor-Free Polymeric Micelle Formulation of Paclitaxel as First-Line Treatment for Ovarian Cancer: a Korean Gynecologic Oncology Group study (KGOG-3021)A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndrome.Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: first-line interventions.Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer.Prediction of therapy response in ovarian cancer: Where are we now?Intraperitoneal chemotherapy after interval debulking surgery for advanced-stage ovarian cancer: Feasibility and outcomes at a comprehensive cancer center.Clinical Development of Anti-mitotic Drugs in Cancer.Targeted therapy of ovarian cancer including immune check point inhibitor.First-Line Chemotherapy for Ovarian Cancer: Inferences From Recent Studies.CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study.Is intraperitoneal chemotherapy still an acceptable option in primary adjuvant chemotherapy for advanced ovarian cancer?Potential role of radiation therapy in augmenting the activity of immunotherapy for gynecologic cancers.Clinicopathologic characteristics associated with long-term survival in advanced epithelial ovarian cancer: an NRG Oncology/Gynecologic Oncology Group ancillary data study.Front-line therapy of advanced ovarian cancer: new approaches.Clinical trials in gynecologic oncology: Past, present, and future.Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer.Advances in ovarian cancer therapy.No need for NMDA receptor antibody screening in neurologically asymptomatic patients with ovarian teratomas.Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models.Front-line therapy of advanced epithelial ovarian cancer: standard treatment.First-line treatment of ovarian cancer: questions and controversies to address.Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.Practice guidelines for management of ovarian cancer in Korea: a Korean Society of Gynecologic Oncology Consensus Statement.Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen?Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients
P2860
Q31125419-0B38BAA9-3286-4749-AEA5-B855FFF9EA94Q33436678-FBC4D4CB-3243-4991-8A4F-52587467976BQ33626973-95A2D01B-3166-47BE-A639-6E2F373C27E0Q33738954-8DD94D95-053E-4DB9-B6DD-6075D3F3CA7AQ36932625-08A63986-EFEA-4696-862E-E2362D35CB3EQ37029841-4E4FB3C3-43C1-4576-9C72-2AF75ADC224BQ37298329-A4291A0A-D22C-421B-80F4-775BF8A70EAEQ37364271-2779A075-1DD9-4D4C-B2D0-B1A4CB503171Q37629090-9E9F12BB-28D5-4694-8E17-585A4C4AF9F8Q37679904-57DA4597-1624-4A22-9859-3807FF5077B9Q37705894-82452ED7-7D81-4064-A38C-3C5902AE4A2EQ38598399-DFB2972C-3128-4CE0-A3C2-21C56BBBF006Q38719990-95F477F3-CA35-49EA-A1A1-9C8ACB5194C2Q38722948-3135D5A4-87CD-4D5D-BAC4-DB6F9B4BAB0AQ38881168-F2E17F7A-E4D7-4F0F-BFFB-6CAEDCC28D01Q38889304-095FEE32-CDDF-487A-9948-7687DF7CD1F6Q39192174-01BA973B-6B9F-4FAE-8F0F-25288026ED2FQ39192789-829A206B-71F0-41C3-A41E-53D81875BD83Q39229584-0587B99B-FE34-4E66-9F28-A0F0E3C270C7Q39263260-4BDD5937-74DD-443C-9710-2F20D0B7CE15Q39332785-E664951D-DC08-4788-B7F5-E95083F56435Q39363642-86FA3959-9652-4BD9-B460-3D50C3F14E8FQ41607677-0F6DF114-580F-4BC0-B611-3046E1D16551Q42933356-282DD97E-F842-4E76-8BC8-7E3044EB28F9Q46085386-B611E419-6CE2-4E66-AF6F-0036D14660B6Q46519965-4F3A934F-E95F-4FF8-9880-14EC0DA9CC34Q46708524-8F4ED82C-181B-4F36-9E60-6DA02FC96D56Q47281811-9DF027BD-47FC-48FA-9CCC-672DAA7C90EBQ47323988-4FB2AD14-4B15-4717-BBF7-BDA1A9916128Q47796770-994D80EF-CA1D-4657-AB22-090B44CC6823Q47993999-CA36819F-98A0-4F9B-990E-44A18775A73EQ48104995-D9FE7AEE-35D9-41D6-AE8D-B678F8C88623Q48353503-2843621F-A635-4DA6-8E8B-5BBCD2632211Q49393542-EEC99363-CEF6-45CD-8ED4-BB1D005A7BB0Q49895978-463511AB-96B8-4E88-BC62-09816C0010CCQ52584387-9D570AFB-7D98-4D3C-A8D6-2D801EF76391Q53054061-42690047-F72E-4246-A0E4-8E69618E0C55Q55493644-4BA0D415-124D-4210-9E10-2ACB27E345C9Q58766423-BFB2E7A4-CB0D-4C2D-9074-243359EF1433Q58778223-E50C4604-B9EA-46E2-9B99-FA752880000C
P2860
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on February 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
@en
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
@nl
type
label
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
@en
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
@nl
prefLabel
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
@en
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
@nl
P2093
P2860
P356
P1476
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
@en
P2093
Bradley J Monk
David M O'Malley
Helen Huang
Helen Michael
Joan L Walker
John K Chan
Lainie P Martin
Mark F Brady
Matthew P Boente
Michael J Birrer
P2860
P304
P356
10.1056/NEJMOA1505067
P407
P577
2016-02-01T00:00:00Z